Aaron Locklear
Family Medicine · Pembroke, NCNPI 1265852685
Payments from drug & device makers
Across 172 payments — averaging $17.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$594
- Novo Nordisk$517
- AstraZeneca$285
- Ardelyx, Inc.$253
- Lilly USA, LLC$211
- Phathom Pharmaceuticals, Inc.$144
- plus $1K from 18 others
What the payments were for
- Food & beverage$2,99398%
- Education$602%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 30 | $594 |
| Novo Nordisk | 32 | $517 |
| AstraZeneca | 18 | $285 |
| Ardelyx, Inc. | 10 | $253 |
| Lilly USA, LLC | 12 | $211 |
| Phathom Pharmaceuticals, Inc. | 6 | $144 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $130 |
| Corcept Therapeutics | 8 | $129 |
| Boehringer Ingelheim | 6 | $102 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $100 |
| Amgen | 7 | $96 |
| Pfizer | 6 | $88 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $77 |
| Sanofi-aventis U.S. LLC | 4 | $64 |
| GSK | 3 | $43 |
| Exact Sciences | 2 | $38 |
| Otsuka America Pharmaceutical, Inc. | 2 | $36 |
| Boston Scientific | 1 | $32 |
| Organogenesis Inc. | 1 | $31 |
| Dynavax Technologies Corporation | 2 | $29 |
| Dexcom, Inc. | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $15 |
| Novartis | 1 | $14 |
| Merck | 1 | $11 |
How this compares
$3,053 in reported general payments places this provider in the 80th percentile of 3,444 family medicine providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 89 | $128,927 |
| LinzessLinaclotide | 100 | $105,261 |
| MounjaroTirzepatide | 53 | $71,815 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 67 | $65,667 |
| JardianceEmpagliflozin | 47 | $62,861 |
| OtezlaApremilast | 13 | $62,167 |
| EliquisApixaban | 49 | $60,447 |
| RybelsusSemaglutide | 32 | $47,181 |
| VraylarCariprazine Hcl | 25 | $35,985 |
| TrulicityDulaglutide | 19 | $30,384 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 48 | $29,449 |
| FarxigaDapagliflozin Propanediol | 21 | $24,455 |
| Tresiba Flextouch U-200Insulin Degludec | 21 | $17,411 |
| TrintellixVortioxetine Hydrobromide | 26 | $17,352 |
| WegovySemaglutide | 13 | $16,767 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Wegovy | $517 | $192,875134 claims |
| Boehringer IngelheimSynjardy Xr, Jardiance, Stiolto Respimat, Combivent Respimat | $102 | $143,817147 claims |
| AbbVieLinzess, Vraylar | $594 | $141,247125 claims |
| Lilly USA, LLCMounjaro, Trulicity | $211 | $102,19972 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Symbicort, Brilinta | $285 | $78,573131 claims |
| AmgenOtezla | $96 | $62,16713 claims |
| PfizerEliquis | $88 | $60,44749 claims |
| GSKAnoro Ellipta, Shingrix | $43 | $26,44789 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $77 | $17,35226 claims |
| NovartisEntresto | $14 | $15,81117 claims |
| MerckJanumet | $11 | $15,60118 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $130 | $6,17811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,444 family medicine providers in North Carolina.
Other family medicine in Pembroke
- Barton WilliamsWilmington$17.3M
- Alexander MurrayGreensboro$13M
- Arin PiramzadianJacksonville$13M
- Jonathan WilsonHickory$12.7M
- George RaadCharlotte$7.7M
- Cecil FarringtonSalisbury$6.4M
- Christian MartinShelby$5.4M
- John EarlHickory$4.7M
- Patrick MorganteHavelock$4.6M
- Stephen JonesShelby$4.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.